ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatocellular carcinoma"

  • 2020 American Transplant Congress

    Effects of Mandatory 6-Month Waiting Time Policy on Post-Transplant Outcomes and Explant Pathology in Liver Transplant Patients with Hepatocellular Carcinoma

    S. Nagai, T. Kitajima, S. Yeddula, R. Salgia, M. Abouljoud, D. Moonka

    Henry Ford Hospital, Detroit, MI

    *Purpose: In the United States, current allocation policy mandates a 6-month waiting period before exception scores are granted to liver transplant (LT) candidates with hepatocellular…
  • 2020 American Transplant Congress

    The Prognostic Impacts of Recipient Gender in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma

    K. Sasaki, M. Sanghvi, M. Fujiki, T. Diago Uso, B. Eghtesad, C. Quintini, C. MIller, K. Hashimoto, C. D. Kwon, F. Aucejo

    The Cleveland Clinic, Cleveland, OH

    *Purpose: Hepatocellular carcinoma (HCC) is significantly male predominant cancer. Sex hormonal signal is considered to play some roles, although exact underlying mechanisms are not fully…
  • 2020 American Transplant Congress

    Everolimus-Treatment Inhibits the Transition of the Immature Subsets of Liver Natural Killer Cells to Mature State and Enhances Anti-Tumor Activity

    Y. Tanaka, J. Saparbay, H. Ohdan

    Gastreenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan

    *Purpose: The immunosuppressive regimen currently used after organ transplantation efficiently reduces the adaptive immune components. During suppressed adaptive immunity, the innate immune cells may play…
  • 2020 American Transplant Congress

    National Trends in Locoregional Therapy among Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) in the United States

    A. Kwong1, W. Kim1, F. Yao2, N. Mehta2

    1Stanford University, Redwood City, CA, 2University of California, San Francisco, San Francisco, CA

    *Purpose: Advances in locoregional therapy (LRT) have expanded treatment options for patients with HCC. As recent policy changes in the United States (US) have lengthened…
  • 2020 American Transplant Congress

    Post-Transplant Recurrence Following Yttrium-90 Treatment in Liver Transplant Recipients with Hepatocellular Carcinoma

    O. Rizzo, T. Kitajima, M. Kavousi, S. Yeddula, M. Rizzari, K. Collins, A. Yoshida, M. S. Abouljoud, S. Nagai

    Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI

    *Purpose: Yttrium-90 microspheres radioembolization (Y90) has shown to be effective as a bridging therapy for patients with advanced hepatocellular carcinoma (HCC) while on waiting list…
  • 2020 American Transplant Congress

    Potential Benefits of Y-90 Radiation Microspheres for Bridging Liver Candidates with Hepatocellular Carcinoma to Liver Transplant

    S. Pelletier1, J. Durden2, S. Shan2, P. Vargas3, N. Goldaracena1

    1University of Virginia Health System, Charlottesville, VA, 2School of Medicine, University of Virginia Health System, Charlottesville, VA, 3Department of Surgery, University of Virginia Health System, Charlottesville, VA

    *Purpose: In October 2015, the UNOS policy for hepatocellular carcinoma (HCC) exception scores was changed to modify the maximum exception value and prolong the time…
  • 2020 American Transplant Congress

    Imaging Features and Diagnostic Accuracy of MRI in Combined Hepatocholangiocarcinoma

    M. Najjar1, J. Makkar1, S. Sun1, J. Zou1, O. Perez1, P. Jiang1, Y. Saenger1, E. Zheng1, E. Verna1, A. Mathur1, A. Griesemer1, K. Halazun2, B. Samstein2, T. Kato1, J. Emond1

    1Columbia University Medical Center/New-York Presbyterian, New York, NY, 2Weill Cornell Medicine, New York, NY

    *Purpose: Combined hepatocholangiocarcinomas (HCC-CCA) are rare tumors with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) differentiations. They are usually associated with a worse prognosis after…
  • 2020 American Transplant Congress

    Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver Derived Natural Killer Cells

    M. Ohira1, R. Hotta1, Y. Imaoka1, K. Sato1, N. Tanimine1, H. Tahara1, K. Ide1, T. Kobayashi1, Y. Tanaka1, A. Tzakis2, S. Nishida2, H. Ohdan1

    1Hiroshima University, Hiroshima, Japan, 2University of Miami, Miami, FL

    *Purpose: Development of an effective adjuvant therapy to prevent HCC recurrence after liver transplantation (LT) is an important medical requirement. Immunosuppressive regimens currently used after…
  • 2020 American Transplant Congress

    Efficacy of Radiofrequency Ablation in the Treatment of Patients with Hepatocellular Carcinoma and Compensated Liver Disease: A Pathological Evaluation of Liver Explants

    W. Alhamoudi1, I. Salih2, S. Yousif2, M. Shawkat3, K. Bzeizi2, A. Albenmousa2, S. Alghamdi2, M. Sturdevant2, D. Broering2, H. Alsuhaibani2

    1Medicine, King Saud University, Riyadh, Saudi Arabia, 2Liver Transplant, King Faisal Specialist Hospital, Riyadh, Saudi Arabia, 3Internal Medicine, Minia University, Minia, Egypt

    *Purpose: Radiofrequency ablation (RFA) is a safe and effective treatment for patients with limited hepatocellular carcinoma (HCC). Ablative outcomes have been largely based on radiological…
  • 2020 American Transplant Congress

    Cirrhosis-Driven Immune Dysfunction is Associated with Poor Response to DEB-TACE and Waitlist Dropout in Hepatocellular Carcinoma Patients While Awaiting Liver Transplantation

    K. Nunez, T. Sandow, M. Hibino, A. Cohen, P. Thevenot

    Ochsner Health System, New Orleans, LA

    *Purpose: Hepatocellular carcinoma (HCC) recurrence after transplantation is associated with higher tumor grade on explant, failure to respond to DEB-TACE, and pretreatment lymphopenia. We prospectively…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences